Interactome analysis reveals ezrin can adopt multiple conformational states

Journal of Biological Chemistry

Volumn 288, Issue 49, 2013, Pages 35500-35510

  Viswanatha, Raghuvir ^a   Wayt, Jessica ^a   Ohouo, Patrice Y ^a   Smolka, Marcus B ^a   Bretscher, Anthony ^a  

^a School of Integrative Plant Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFORMATIONS; MASS SPECTROMETRY;

ACTIVATION MODELS; CONFORMATIONAL STATE; EPITHELIAL CELLS; INTERACTOME; INTERACTORS; MICROFILAMENTS; MICROVILLI; QUANTITATIVE MASS SPECTROMETRIES;

PROTEINS;

EZRIN; CORE BINDING FACTOR; CYTOSKELETON PROTEIN; LIGAND; PHOSPHOPROTEIN; PROTEIN BINDING; PROTEOME; RECOMBINANT PROTEIN; SODIUM PROTON EXCHANGE PROTEIN; SODIUM-HYDROGEN EXCHANGER REGULATORY FACTOR;

ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; MICROVILLUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; QUANTITATIVE ANALYSIS; WILD TYPE; AMINO ACID SUBSTITUTION; CELL LINE; CHEMISTRY; GENETICS; HUMAN; MASS SPECTROMETRY; METABOLISM; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; SITE DIRECTED MUTAGENESIS;

AMINO ACID SUBSTITUTION; CELL LINE; CORE BINDING FACTORS; CYTOSKELETAL PROTEINS; HUMANS; LIGANDS; MASS SPECTROMETRY; MICROVILLI; MUTAGENESIS, SITE-DIRECTED; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; PROTEOME; RECOMBINANT PROTEINS; SODIUM-HYDROGEN ANTIPORTER;

EID: 84894339622     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.505669     Document Type: Article

References (75)

1. Coyle, J. T., and Duman, R. S. (2003) Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38, 157-160
2. Licht, R. W. (2012) Lithium. Still a major option in the management of bipolar disorder. CNS Neurosci. Ther. 18, 219-226
3. Alvarez, G., Muñoz-Montaño, J. R., Satrústegui, J., Avila, J., Bogónez, E., and Díaz-Nido, J. (2002) Regulation of tau phosphorylation and protection against -amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar. Disord. 4, 153-165
4. Nunes, P. V., Forlenza, O. V., and Gattaz, W. F. (2007) Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br. J. Psychiatry 190, 359-360
5. Macdonald, A., Briggs, K., Poppe, M., Higgins, A., Velayudhan, L., and Lovestone, S. (2008) A feasibility and tolerability study of lithium in Alzheimer's disease. Int. J. Geriatr. Psychiatry 23, 704-711
6. Quinn, N., and Marsden, C. D. (1986) Lithium for painful dystonia in Parkinson's disease. Lancet 1, 1377
7. Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., Burns, M., Krishnamurthy, P., Wen, Y., Bhat, R., Lewis, J., Dickson, D., and Duff, K. (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. U.S.A. 102, 6990-6995
8. Sarkar, S., Floto, R. A., Berger, Z., Imarisio, S., Cordenier, A., Pasco, M., Cook, L. J., and Rubinsztein, D. C. (2005) Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 170, 1101-1111
9. Wei, H., Qin, Z. H., Senatorov, V. V., Wei, W., Wang, Y., Qian, Y., and Chuang, D. M. (2001) Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 106, 603-612
10. Wood, N. I., and Morton, A. J. (2003) Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation. Brain Res. Bull. 61, 375-383
11. Kaufmann, L., Marinescu, G., Nazarenko, I., Thiele, W., Oberle, C., Sleeman, J., and Blattner, C. (2011) LiCl induces TNF- and FasL production, thereby stimulating apoptosis in cancer cells. Cell Commun. Signal 9, 15
12. Song, L., Zhou, T., and Jope, R. S. (2004) Lithium facilitates apoptotic signaling induced by activation of the Fas death domain-containing receptor. BMC Neurosci. 5, 20
13. Zhang, W. V., Jüllig, M., Connolly, A. R., and Stott, N. S. (2005) Early gene response in lithium chloride induced apoptosis. Apoptosis 10, 75-90
14. Wang, Q., Xu, X., Li, J., Liu, J., Gu, H., Zhang, R., Chen, J., Kuang, Y., Fei, J., Jiang, C., Wang, P., Pei, D., Ding, S., and Xie, X. (2011) Lithium, an antipsychotic drug, greatly enhances the generation of induced pluripotent stem cells. Cell Res. 21, 1424-1435
15. Stump, R. J., Lovicu, F. J., Ang, S. L., Pandey, S. K., and McAvoy, J. W. (2006) Lithium stabilizes the polarized lens epithelial phenotype and inhibits proliferation, migration, and epithelial mesenchymal transition. J. Pathol. 210, 249-257
16. Stambolic, V., Ruel, L., and Woodgett, J. R. (1996) Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr. Biol. 6, 1664-1668
17. Jope, R. S. (2003) Lithium and GSK-3. One inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol. Sci. 24, 441-443
18. Coghlan, M. P., Culbert, A. A., Cross, D. A., Corcoran, S. L., Yates, J. W., Pearce, N. J., Rausch, O. L., Murphy, G. J., Carter, P. S., Roxbee Cox, L., Mills, D., Brown, M. J., Haigh, D., Ward, R. W., Smith, D. G., Murray, K. J., Reith, A. D., and Holder, J. C. (2000) Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 7, 793-803
19. Grimes, C. A., and Jope, R. S. (2001) The multifaceted roles of glycogen synthase kinase 3- in cellular signaling. Prog. Neurobiol. 65, 391-426
20. Morfini, G., Szebenyi, G., Elluru, R., Ratner, N., and Brady, S. T. (2002) Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J. 21, 281-293
21. Hanger, D. P., Anderton, B. H., and Noble, W. (2009) Tau phosphorylation. The therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 15, 112-119
22. Vincent, T., Kukalev, A., Andäng, M., Pettersson, R., and Percipalle, P. (2008) The glycogen synthase kinase (GSK) 3- repressesRNApolymerase I transcription. Oncogene 27, 5254-5259
23. Yorimitsu, T., and Klionsky, D. J. (2005) Autophagy. Molecular machinery for self-eating. Cell Death Differ. 12, 1542-1552
24. Mizushima, N., Levine, B., Cuervo, A. M., and Klionsky, D. J. (2008) Autophagy fights disease through cellular self-digestion. Nature 451, 1069-1075
25. Cuervo, A. M., Bergamini, E., Brunk, U. T., Dröge, W., Ffrench, M., and Terman, A. (2005) Autophagy and aging. The importance of maintaining "clean" cells. Autophagy 1, 131-140
26. Debnath, J., Baehrecke, E. H., and Kroemer, G. (2005) Does autophagy contribute to cell death Autophagy 1, 66-74
27. Gozuacik, D., and Kimchi, A. (2004) Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23, 2891-2906
28. Kondo, Y., Kanzawa, T., Sawaya, R., and Kondo, S. (2005) The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 5, 726-734
29. Levine, B., and Kroemer, G. (2008) Autophagy in the pathogenesis of disease. Cell 132, 27-42
30. Mizushima, N., and Komatsu, M. (2011) Autophagy. Renovation of cells and tissues. Cell 147, 728-741
31. Heiseke, A., Aguib, Y., Riemer, C., Baier, M., and Schätzl, H. M. (2009) Lithium induces clearance of protease resistant prion protein in prioninfected cells by induction of autophagy. J. Neurochem. 109, 25-34
32. Marks, P., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., and Kelly, W. K. (2001) Histone deacetylases and cancer. Causes and therapies. Nat. Rev. Cancer 1, 194-202
33. Saha, R. N., and Pahan, K. (2006) HATs and HDACs in neurodegeneration. A tale of disconcerted acetylation homeostasis. Cell Death Differ. 13, 539-550
34. Minucci, S., and Pelicci, P. G. (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6, 38-51
35. Haberland, M., Johnson, A., Mokalled, M. H., Montgomery, R. L., and Olson, E. N. (2009) Genetic dissection of histone deacetylase requirement in tumor cells. Proc. Natl. Acad. Sci. U.S.A. 106, 7751-7755
36. Glozak, M. A., and Seto, E. (2007) Histone deacetylases and cancer. Oncogene 26, 5420-5432
37. MacDonald, M. E., Ambrose, C. M., Duyao, M. P., Myers, R. H., Lin, C., Srinidhi, L., Barnes, G., Taylor, S. A., James, M., Groot, N., MacFarlane, H., Jenkins, B., Anderson, M. A., Wexler, N. S., and Gusella, J. F.; and The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983
38. Jeong, H., Then, F., Melia, T. J., Jr., Mazzulli, J. R., Cui, L., Savas, J. N., Voisine, C., Paganetti, P., Tanese, N., Hart, A. C., Yamamoto, A., and Krainc, D. (2009) Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 137, 60-72
39. Rouaux, C., Jokic, N., Mbebi, C., Boutillier, S., Loeffler, J. P., and Boutillier, A. L. (2003) Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J. 22, 6537-6549
40. Barrachina, M., and Ferrer, I. (2009) DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain. J. Neuropathol. Exp. Neurol. 68, 880-891
41. Sancho-Pelluz, J., Alavi, M. V., Sahaboglu, A., Kustermann, S., Farinelli, P., Azadi, S., van Veen, T., Romero, F. J., Paquet-Durand, F., and Ekström, P. (2010) Excessive HDAC activation is critical for neurodegeneration in the rd1 mouse. Cell Death Dis. 1, e24
42. Jiang, Y. J., Che, M. X., Yuan, J. Q., Xie, Y. Y., Yan, X. Z., and Hu, H. Y. (2011) Interaction with polyglutamine-expanded huntingtin alters cellular distribution and RNA processing of huntingtin yeast two-hybrid protein A (HYPA). J. Biol. Chem. 286, 25236-25245
43. Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G., Schuettengruber, B., Hauser, C., Brunmeir, R., Jenuwein, T., and Seiser, C. (2002) Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 21, 2672-2681
44. Gui, C. Y., Ngo, L., Xu, W. S., Richon, V. M., and Marks, P. A. (2004) Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. U.S.A. 101, 1241-1246
45. Lagger, G., Doetzlhofer, A., Schuettengruber, B., Haidweger, E., Simboeck, E., Tischler, J., Chiocca, S., Suske, G., Rotheneder, H., Wintersberger, E., and Seiser, C. (2003) The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/ WAF1/CIP1 gene. Mol. Cell Biol. 23, 2669-2679
46. Varshochi, R., Halim, F., Sunters, A., Alao, J. P., Madureira, P. A., Hart, S. M., Ali, S., Vigushin, D. M., Coombes, R. C., and Lam, E. W. (2005) ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor- from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line. J. Biol. Chem. 280, 3185-3196
47. Wang, G. L., Salisbury, E., Shi, X., Timchenko, L., Medrano, E. E., and Timchenko, N. A. (2008) HDAC1 cooperates with C/EBP- in the inhibition of liver proliferation in old mice. J. Biol. Chem. 283, 26169-26178
48. Wang, G. L., Salisbury, E., Shi, X., Timchenko, L., Medrano, E. E., and Timchenko, N. A. (2008) HDAC1 promotes liver proliferation in young mice via interactions with C/EBP-. J. Biol. Chem. 283, 26179-26187
49. Fujimura, K., Kano, F., and Murata, M. (2008) Dual localization of the RNA binding protein CUGBP-1 to stress granule and perinucleolar compartment. Exp. Cell Res. 314, 543-553
50. Gareau, C., Fournier, M. J., Filion, C., Coudert, L., Martel, D., Labelle, Y., and Mazroui, R. (2011) p21(WAF1/CIP1) upregulation through the stress granule-associated protein CUGBP1 confers resistance to bortezomibmediated apoptosis. PLoS ONE 6, e20254
51. Chen, H., Wang, N., Burmeister, M., and McInnis, M. G. (2009) MicroRNA expression changes in lymphoblastoid cell lines in response to lithium treatment. Int. J. Neuropsychopharmacol. 12, 975-981
52. Zhou, R., Yuan, P., Wang, Y., Hunsberger, J. G., Elkahloun, A., Wei, Y., Damschroder-Williams, P., Du, J., Chen, G., and Manji, H. K. (2009) Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 34, 1395-1405
53. Hu, K., Zhang, C., Long, L., Long, X., Feng, L., Li, Y., and Xiao, B. (2011) Expression profile of microRNAs in rat hippocampus following lithiumpilocarpine- induced status epilepticus. Neurosci. Lett. 488, 252-257
54. Wada, T., Kikuchi, J., Nishimura, N., Shimizu, R., Kitamura, T., and Furukawa, Y. (2009) Expression levels of histone deacetylases determine the cell fate of hematopoietic progenitors. J. Biol. Chem. 284, 30673-30683
55. Tang, R., Faussat, A. M., Majdak, P., Perrot, J. Y., Chaoui, D., Legrand, O., and Marie, J. P. (2004) Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 18, 1246-1251
56. Catalano, M. G., Fortunati, N., Pugliese, M., Costantino, L., Poli, R., Bosco, O., and Boccuzzi, G. (2005) Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J. Clin. Endocrinol. Metab. 90, 1383-1389
57. Insinga, A., Monestiroli, S., Ronzoni, S., Gelmetti, V., Marchesi, F., Viale, A., Altucci, L., Nervi, C., Minucci, S., and Pelicci, P. G. (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 11, 71-76
58. Cohen, P., and Goedert, M. (2004) GSK3 inhibitors. Development and therapeutic potential. Nat. Rev. Drug Discov. 3, 479-487
59. Beaulieu, J. M., Marion, S., Rodriguiz, R. M., Medvedev, I. O., Sotnikova, T. D., Ghisi, V., Wetsel, W. C., Lefkowitz, R. J., Gainetdinov, R. R., and Caron, M. G. (2008) A -arrestin 2 signaling complex mediates lithium action on behavior. Cell 132, 125-136
60. Rolli-Derkinderen, M., Machavoine, F., Baraban, J. M., Grolleau, A., Beretta, L., and Dy, M. (2003) ERK and p38 inhibit the expression of 4E-BP1 repressor of translation through induction of Egr-1. J. Biol. Chem. 278, 18859-18867
61. Wang, X., Yue, P., Chan, C. B., Ye, K., Ueda, T., Watanabe-Fukunaga, R., Fukunaga, R., Fu, H., Khuri, F. R., and Sun, S. Y. (2007) Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinasedependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol. Cell Biol. 27, 7405-7413
62. Pradelli, L. A., Bénéteau, M., Chauvin, C., Jacquin, M. A., Marchetti, S., Muñoz-Pinedo, C., Auberger, P., Pende, M., and Ricci, J. E. (2010) Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation. Oncogene 29, 1641-1652
63. Kim, J. Y., Shen, S., Dietz, K., He, Y., Howell, O., Reynolds, R., and Casaccia, P. (2010) HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat. Neurosci. 13, 180-189
64. Iakova, P., Wang, G. L., Timchenko, L., Michalak, M., Pereira-Smith, O. M., Smith, J. R., and Timchenko, N. A. (2004) Competition of CUGBP1 and calreticulin for the regulation of p21 translation determines cell fate. EMBO J. 23, 406-417
65. Baldwin, B. R., Timchenko, N. A., and Zahnow, C. A. (2004) Epidermal growth factor receptor stimulation activates the RNA binding protein CUG-BP1 and increases expression of C/EBP-LIP in mammary epithelial cells. Mol. Cell Biol. 24, 3682-3691
66. Timchenko, N. A., Patel, R., Iakova, P., Cai, Z. J., Quan, L., and Timchenko, L. T. (2004) Overexpression of CUG triplet repeat-binding protein, CUGBP1, in mice inhibits myogenesis. J. Biol. Chem. 279, 13129-13139
67. Vlasova, I. A., Tahoe, N. M., Fan, D., Larsson, O., Rattenbacher, B., Sternjohn, J. R., Vasdewani, J., Karypis, G., Reilly, C. S., Bitterman, P. B., and Bohjanen, P. R. (2008) Conserved GU-rich elements mediate mRNA decay by binding to CUG-binding protein Mol. Cell 29, 263-270
68. Pallos, J., Bodai, L., Lukacsovich, T., Purcell, J. M., Steffan, J. S., Thompson, L. M., and Marsh, J. L. (2008) Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet. 17, 3767-3775
69. Wyttenbach, A., Sauvageot, O., Carmichael, J., Diaz-Latoud, C., Arrigo, A. P., and Rubinsztein, D. C. (2002) Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum. Mol. Genet. 11, 1137-1151
70. Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., and Finkbeiner, S. (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810
71. Sarkar, S., Krishna, G., Imarisio, S., Saiki, S., O'Kane, C. J., and Rubinsztein, D. C. (2008) A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum. Mol. Genet. 17, 170-178
72. Carew, J. S., Nawrocki, S. T., Kahue, C. N., Zhang, H., Yang, C., Chung, L., Houghton, J. A., Huang, P., Giles, F. J., and Cleveland, J. L. (2007) Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 110, 313-322
73. Oh, M., Choi, I. K., and Kwon, H. J. (2008) Inhibition of histone deacetylase1 induces autophagy. Biochem. Biophys. Res. Commun. 369, 1179-1183
74. Robert, T., Vanoli, F., Chiolo, I., Shubassi, G., Bernstein, K. A., Rothstein, R., Botrugno, O. A., Parazzoli, D., Oldani, A., Minucci, S., and Foiani, M. (2011) HDACs link the DNA damage response, processing of doublestrand breaks and autophagy. Nature 471, 74-79
75. Sofola, O. A., Jin, P., Qin, Y., Duan, R., Liu, H., de Haro, M., Nelson, D. L., and Botas, J. (2007) RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron 55, 565-571